期刊文献+

泼尼松龙与地塞米松介导腰椎骨量降低的差异及其对成骨成脂基因表达的影响 被引量:4

Difference investigation of the lumbar bone-loss level induced by prednisolone or dexamethasone and its effects on osteogenic and adipogenic gene expression
下载PDF
导出
摘要 目的:比较泼尼松龙(PRE)和地塞米松(DXM)诱导腰椎骨量丢失差异程度并利用成脂成骨经典信号通路探讨其可能机制。方法:选取3月龄SPF级雌性大鼠24只,随机分成4组:基线组(BL组)6只、年龄对照组(CON组)6只、泼尼松龙组(PRE组)6只、地塞米松组(DXM组)6只。BL组于实验开始时麻醉处死,其余3组正常喂养,其中CON组不作任何药物干预,PRE组予5mg/kg PRE每天一次皮下注射、DXM组以1mg/kg DXM每周两次皮下注射。干预3个月后麻醉下取材。取材时立即分离右侧股骨,获取髓腔内骨髓细胞进行涂片,油红“O”检测骨髓性状;取L6椎体作反转录式-聚合酶连锁反应(RT-PCR)检测骨保护素(OPG)及过氧化物酶体增殖物激活受体γ(PPAR-γ)表达;分离L1~L3椎体检测骨密度(BMD)。结果:在两种糖皮质激素(GC)分别干预3个月后,其BMD值均较CON组有明显下降(P〈0.05),DXM组下降更为显著(P〈0.01),且明显低于PRE组(P〈0.05)。DXM组骨组织OPG表达量明显低于其余三组(P〈0.05),但PPAR-γ则组间无明显差异。骨髓油红“O”涂片发现,两种GC组涂片阳性细胞数量多于BL组和CON组,但其组间无明显差异。结论:两种不同的糖皮质激素在诱导大鼠骨量丢失模型中,地塞米松诱导腰椎骨量减少的效果较泼尼松龙强,这可能与DXM通过OPG/RANKL/RANK信号通路中更大程度地抑制OPG表达有关。 Objectives: To investigate tile mechanism of lumbar bone loss induced by prednisolone(PRE) or dexamethasone(DXM) through the osteogenesis and adipogenesis pathway. Methods: 24 female SD rats aged 3 months was divided into 4 groups randomly as below, baseline group(BL group, 6 rats), age-matched control group(CON group, 6 rats), prednisolone-treated group(PRE group, 6 rats), dexamethasone-treated group(DXM group, 6 rats). BL group were euthanized at the beginning of the experiment and CON group rats were feed normally with no treatment. PRE group and DXM group were injected with PRE in a dose of 5mg/kg per day and DXM in a dose of lmg/kg twice per week, respectively and lasted for 3 months. The bone marrow in right femur was collected for Oil red staining to observe the cell types, lumbar 6 was collected for testing the activity of osteoprotegerin(OPG) and peroxisome proliferator activated receptor-3,(PPAR-y) by reverse transcrip- tion-polymerase chain reaction(RT-PCR), lumbar 1-3 were collected for BMD at the end of treatment. Re- suits: BMD in PRE and DXM rats were lower than CON rats, and decreased more significantly in DXM rats (P〈0.01). Moreover, DXM rats decreased more significantly compared with PRE rats in BMD. Although the expression level of PPAR-γ had no significant difference among 4 groups, OPG in DXM rats was lower than that in other groups. The amount of red-staining cell in two glucocorticoid treated rats were more than that of BL group, but there was no obvious difference between the treated groups. Conclusions: The effect of DXM on lumbar bone mass decrease is more powerful than that of PRE, which expression of OPG more significantly through OPG/RANKL/RANK pathway.
出处 《中国脊柱脊髓杂志》 CAS CSCD 北大核心 2015年第2期168-173,共6页 Chinese Journal of Spine and Spinal Cord
基金 广东省教育厅学科建设专项基金(育苗工程)[2013LYM-0012] 广州中医药大学优秀青年学者科研基金项目(KAB110133K04)
关键词 糖皮质激素 骨质疏松 OPG PPAR-Γ Glucocorticoid Bone mineral density OPG PPAR-γ
  • 相关文献

参考文献1

二级参考文献14

  • 1金慰芳,于志锋,高建军,顾淑珠,周轶,王洪复.PTH对骨髓细胞骨代谢相关基因表达的影响[J].中国骨质疏松杂志,2005,11(3):286-288. 被引量:11
  • 2Beresford JN.Osteogenic stem cells and the stromal system of bone and marrow.Clin Orthop Relat Res,1989,240:270-280.
  • 3Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells.Science,1999,284 (5411):143-147.
  • 4Nuttall ME,Patton AJ,Olivera DL,et al.Human traebecular bone cells are able to express both osteoblastic and adipocytic phenotype:Implications for osteogenic disorders.J Bone Miner Res,1998,13(3):371-382.
  • 5Park SR,Oreffo RO,Triffitt JT.Interconversion potential of cloned human marrow adipocytes in vitro.Bone,1999,24(6):549-554.
  • 6Rosen ED,Spiegelman BM.Molecular regulation of adipogenesis.Annu Rev Cell Dev Biol,2000,16:145-171.
  • 7Desvergne B,Wahli W.Peroxisome proliferator-activated receptors:Nuclear control of metabolism.Endocr Rev,1999,20(5):649-688.
  • 8Ogawa S,Urano T,Hosoi T.Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene:PPAR gamma expression in osteoblasts.Biochem Biophys Res Commun,1999,260(1):122-126.
  • 9Spelsberg TC,Subramaniam M,Riggs BL,et al.The actions and interactions of sex steroids and growth factors/cytokines on the skeleton.Mol Endocrinol,1999,13(6):819-828.
  • 10Schiller PC,D'Ippolito G,Brambilla R,et al.Inhibition of gapjunctional communication induces the trans-differentiation of osteoblasts to an adipocytic phenotype in vitro.J Biol Chem,2001,276(17):14133-14138.

共引文献2

同被引文献50

  • 1Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl .I Med, 2011,365(1) :62-70.
  • 2Lekamwasam S, Adaehi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocortieoid-induced osteoporosis. Osteoporos Int, 2012, 23 (9) :2257-2276.
  • 3Overman RA, Yeh JY, Deal CL. Prevalence of oral glncocortieoid usage in the United States: a general population perspective. Arthritis Care Res ( Hoboken ) , 2013,65 ( 2 ) : 294- 298.
  • 4Fardet L, Petersen I, Nazareth I. Description of oral glucocorticoid prescriptions in general population. Rev Med Interne ,2011,32 ( 10 ) :594-599.
  • 5Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol,2010,6 (2) :82-88.
  • 6Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res,2004,19 (6) :893-899.
  • 7Kanis JA, Stevenson M, McCloskey EV, et al. Glucocorticoid- induced osteoporosis : a systematic review and cost-utility analysis. Health Technol Assess ,2007,11 (7) : 1-231.
  • 8Chrisehilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone, 1994,15 (4) : 377-386.
  • 9Mukwaya E, Xu F, Wong MS, et al. Chinese herbal medicine for bone health. Pharm Biol,2014,52(9) :1223-1228.
  • 10den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid- induced osteoporosis. Curr Rheumatol Rep, 2011,13 ( 3 ) : 233- 240.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部